Abstract #4978

Anti-angiogenic treatment alters stiffness of glioblastoma in an orthotopic mouse model

Katharina Schregel^1,2,3, Michal Oskar Nowicki⁴, Miklos Palotai^2,3, Navid Nazari⁵, Rachel Zane⁴, Ralph Sinkus⁶, Sean Lawler^3,4, and Samuel Patz^2,3

¹Institute of Neuroradiology, University Medical Center Goettingen, Goettingen, Germany, ²Department of Radiology, Brigham and Women's Hospital, Boston, MA, United States, ³Harvard Medical School, Boston, MA, United States, ⁴Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, United States, ⁵Department of Biomedical Engineering, Boston University, Boston, MA, United States, ⁶Department of Radiological Imaging, Imaging Sciences & Biomedical Engineering Division, King's College London, London, United Kingdom

Glioblastoma (GBM) is the most common malignant brain tumor. As it is highly vascularized, anti-angiogenic treatment strategies have been tested. Such treatment hinders radiological tumor monitoring. Here, we probed the potential of magnetic resonance elastography (MRE) to evaluate GBM treated with anti-angiogenic therapy. GBM was orthotopically implanted in 10 nude mice, of which 5 were treated with B20 anti-VEGF antibody. MRI and MRE were performed repeatedly and brains were harvested for histology afterwards. Anti-angiogenic treatment slowed tumor growth, affected contrast-enhancement and slowed down tumor softening. The phase angle Y expressing the solid/liquid ratio appeared to indicate tumor progression.

This abstract and the presentation materials are available to members only; a login is required.

Join Here